Mitchell Kronenberg

Title: Innovations of Mitchell Kronenberg

Introduction

Mitchell Kronenberg is a notable inventor based in Del Mar, California. He has made significant contributions to the field of immunology, particularly through his research on T cell activation and modulation.

Latest Patents

Kronenberg holds a patent titled "Compositions and methods for modulating responses mediated or associated with BTLA activity." This patent focuses on the Herpesvirus entry mediator (HVEM), which is a member of the tumor necrosis factor receptor superfamily. HVEM acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF-related ligand, LIGHT, or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). His research discloses a novel binding site for BTLA located in cysteine-rich domain-1 of HVEM. This binding site overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D, but is distinct from where LIGHT binds. Notably, gD inhibits the binding of both ligands. Additionally, a BTLA activating protein present in human cytomegalovirus, identified as UL144, binds BTLA but not LIGHT, inhibiting T cell proliferation.

Career Highlights

Kronenberg is affiliated with the La Jolla Institute for Allergy and Immunology, where he continues to advance research in immunology. His work has implications for understanding immune responses and developing therapeutic strategies.

Collaborations

He has collaborated with notable colleagues, including Carl F. Ware and Carl De Trez, contributing to the advancement of knowledge in his field.

Conclusion

Mitchell Kronenberg's innovative work in immunology, particularly regarding T cell modulation, showcases his significant contributions to science and medicine. His patent reflects a deep understanding of complex biological interactions, paving the way for future research and potential therapies.